10.12.2020 16:00:56

Edwards Lifesciences Sees FY21 Adj. EPS Below View

(RTTNews) - Edwards Lifesciences Corp. (EW) presents long-term strategic initiatives and growth outlook at its annual investor conference. It expects 2021 adjusted earnings per share to be in the range of $2.00 - $2.20. Analysts polled by Thomson Reuters expect the company to report earnings of $2.22 per share for fiscal year 2021. Analysts' estimates typically exclude special items.

The company projects 2021 global sales of $4.9 billion-$5.3 billion; underlying growth in the mid-teens. Analysts expect annual revenues of $5.1 billion.

The company projects 2021 Transcatheter Aortic Valve Replacement or TAVR sales of $3.2 billion- $3.6 billion; underlying growth of 15%-20%.

Edwards continues to believe the global TAVR opportunity will reach $7+ billion by 2024, with continuing growth thereafter, fueled by therapy expansion, technology advances and geographic expansion.

The company noted that it is currently integrating a full range of technologies on the HemoSphere monitoring platform. In addition, Edwards anticipates the launch of its Viewfinder connectivity solution in 2021.

Analysen zu Edwards Lifesciences Corp.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Edwards Lifesciences Corp. 71,90 1,05% Edwards Lifesciences Corp.